ClinicalTrials.gg
TerminatedNCT06297642Updated Aug 6, 2024

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.

A Phase 1 interventional study of TQB2928 injection and Penpulimab in Advanced Malignant Neoplasm, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Terminated at 5 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Why this study was terminated
Based on the current status of the same target research and the company's overall layout in the field of tumors, the early termination was determined after full communication with the principal investigator of the group leader unit.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study will evaluate the safety and efficiency of TQB2928 injection combined with Penpulimab in the treatment of patients with advanced malignant tumors.

02

Conditions studied

  • Advanced Malignant Neoplasm
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily participate in this study and sign ;
  • Age: ≥18 years old (when signing the informed consent form); (ECOG) score: 0 or 2 point; The expected survival period exceeds 3 months;
  • Subject population: and/or cytologically confirmed advanced , including lymphomas and solid tumors.
  • Relapse or treatment failure after previous standard treatment, or intolerance to standard treatment and no other better treatment options:
  • Adequate treatment with /PD-L1 (including monotherapy or combination) without remission or disease progression after treatment.
  • Adequate main organs function
  • Female subjects of childbearing age should agree to use (such as Intrauterine device, contraceptives or condoms) during the study period and within 6 months after the end of the study; The serum or urine Pregnancy test was negative within 7 days before the study was included, and must be non-lactating subjects; Male participants should agree to use contraception during the study period and within 6 months after the end of the study period.

Exclusion criteria

Exclusion Criteria:

  • Tumor disease and history:

    1. Nodular lymphocyte dominant Hodgkin's lymphoma or gray area lymphoma.
    2. The tumor involves the central nervous system.
    3. People with a history of hemophagocytic syndrome or who have been assessed by the investigator as being at suspected risk.
    4. Has experienced or currently suffers from other malignant tumors within 3 years.
  • Previous anti-tumor therapy:

    1. Previous use of other similar drugs.
    2. received systemic antitumor drugs (including drugs under investigation) within 4 weeks prior to initial administration, or received Chimeric Antigen Receptor T-cell (CAR-T) Therapy or hematopoietic stem cell transplantation( auto-HSCT) within 3 months prior to initial administration.
    3. Previously received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
    4. any major surgical procedure, chemotherapy and/or radiotherapy, immunotherapy, or targeted therapy within 4 weeks prior to initial dosing.
    5. Less than 5 drug half-lives between the first administration and the previous oral targeted therapy (calculated from the end time of the last therapy).
    6. Received within 2 weeks before the first administration of Chinese patent drugs (including compound cantharides capsule, Kangai injection, Kanglaite capsule/injection, Aidi injection, Brucea oil injection/capsule, Xiaoaiping tablet/injection, cinobufagin capsule, etc.) approved by the National Drug Administration (NMPA) with anti-tumor indications.
  • Concomitant diseases and medical history:

    1. Liver abnormalities:
    2. Abnormal kidney:
    3. Cardiovascular and cerebrovascular abnormalities:
    4. History of immune deficiency:
    5. Lung diseases:
    6. Active bacterial, fungal, or viral infections requiring systemic treatment.
    7. Subjects with a history of hemolytic anemia from any cause (including Evans syndrome) or a positive Coombs test within 3 months prior to initial dosing.
    8. A prior history of unexplained severe allergies, known to be allergic to monoclonal drugs or exogenous human immunoglobulins.
    9. with a serious or poorly controlled disease that, in the judgment of the investigator and sponsor, poses a serious risk to the safety of the subjects or affects the completion of the study.
    10. History of drug abuse or drug use.
  • were administered within 4 weeks before the first dose or during the planned study period. Inactivated Corona Virus Disease 2019 (COVID-19) and influenza vaccines are allowed.
  • Subjects with concomitant diseases that, in the judgment of the investigator, seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are not suitable for enrollment for other reasons.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    TQB2928 injection + Penpulimab

    TQB2928 injection combined with Penpulimab, 21 days as a treatment cycle.

    Drug: TQB2928 injection · Drug: Penpulimab

Interventions

  • Anti-CD47 monoclonal antibody

  • Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)

    The relevant adverse reactions occurred within the first cycle

    Time frame: Baseline up to 3 weeks

  2. Adverse event rate

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

    Time frame: Baseline up to 96 weeks

Secondary outcomes

  1. Objective response rate (ORR)

    Percentage of participants achieve complete response and partial response

    Time frame: Baseline up to 96 weeks

  2. Complete response rate (CRR)

    Percentage of participants achieve complete response

    Time frame: Baseline up to 96 weeks

  3. Disease Control Rate

    It is the proportion of patients whose tumors have shrunk or stabilized for a certain amount of time and includes complete response (CR), partial response (PR), and stable (SD) cases

    Time frame: Baseline up to 96 weeks

  4. Duration of Response

    The time when the participants first achieved CR or PR to disease progression or death from any cause

    Time frame: Baseline up to 96 weeks

  5. Progression-free Survival

    The period between the beginning of treatment and the observation of disease progression or death from any cause in a patient with a tumor disease

    Time frame: Baseline up to 96 weeks

  6. Overall survival (OS)

    From the first injection to the time of death from any cause.

    Time frame: Baseline up to 96 weeks

  7. Incidence of Anti-Drug antibody

    The incidence of anti-drug antibody after administration of TQB2928 injection and penpulimab

    Time frame: Cycle 1 day 1, Cycle 5 day 1, and 28 days, 90 days after the last administration. (Each cycle 21 days)

  8. Incidence of neutralizing antibodies

    The incidence of neutralizing antibodies after administration of TQB2928 injection and penpulimab

    Time frame: Cycle 1 day 1, Cycle 5 day 1, and 28 days, 90 days after the last administration. (Each cycle 21 days)

  9. Peak time (Tmax)

    The time to peak concentration

    Time frame: Day 1, day 2 , day 4 , day 6 , day 8, day15 of cycle 1 and cycle 2. Each cycle 21 days.

  10. Peak concentration (Cmax)

    Maximum plasma drug concentration

    Time frame: Day 1, day 2 , day 4 , day 6 , day 8, day15 of cycle 1 and cycle 2. Each cycle 21 days.

  11. The area under the plasma concentration time curve from zero to after 24h (AUC0-24h)

    Area under the plasma concentration time curve from zero to after 24h for TQB2928.

    Time frame: Day 1, day 2 , day 4 , day 6 , day 8, day15 of cycle 1 and cycle 2. Each cycle 21 days.

  12. Steady-state apparent volume of distribution (Vz/F)

    The total volume of body fluid required by the measured plasma drug concentration after the total amount of drug in the body is to be balanced.

    Time frame: Day 1, day 2 , day 4 , day 6 , day 8, day15 of cycle 1 and cycle 2. Each cycle 21 days.

  13. Minimum plasma concentration at steady state (Cmin,ss)

    The minimum plasma concentration after stabilization

    Time frame: Day 1, day 2 , day 4 , day 6 , day 8, day15 of cycle 1 and cycle 2. Each cycle 21 days.

  14. Receptor Occupancy (RO%)

    The extent to which antibody drugs occupy cell surface targets

    Time frame: day 1 and day 8 of Cycle 1, day 1 and day 15 of Cycle 2, 28 days after the last administration. (each cycle 21 days)

07

Study locations

5 sites
  • The Second People's Hospital of Hefei
    Hefei, Anhui 230012, China
  • Lu'an People's Hospital of Anhui Province
    Lu'an, Anhui 237008, China
  • Cancer Hospital Chinese Academy of Medical Science
    Beijing, Beijing 100021, China
  • Gansu Provincial Cancer Hospital
    Lanzhou, Gansu 730000, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Jul 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 7, 2024
StartActual
May 24, 2024
Primary completionActual
Jul 31, 2024
CompletionActual
Jul 31, 2024
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06297642
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
May 24, 2024
Primary completion
Jul 31, 2024
Completion
Jul 31, 2024
Last update
Aug 6, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CD47/SIRPa Blocking Agent TQB2928 · Penpulimab

Start the discussion